What is HC Wainwright’s Estimate for GLSI FY2024 Earnings?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of Greenwich LifeSciences in a report issued on Tuesday, February 11th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.80) for the year, up from their previous estimate of ($0.81). HC Wainwright has a “Buy” rating and a $38.00 price objective on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ FY2025 earnings at ($0.81) EPS.

Greenwich LifeSciences Stock Performance

NASDAQ GLSI opened at $12.38 on Friday. The company has a market capitalization of $162.80 million, a PE ratio of -15.47 and a beta of 1.69. The business’s fifty day moving average is $12.62 and its 200 day moving average is $13.52. Greenwich LifeSciences has a fifty-two week low of $9.91 and a fifty-two week high of $21.44.

Insider Activity at Greenwich LifeSciences

In related news, CEO Snehal Patel bought 2,500 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were bought at an average cost of $12.51 per share, for a total transaction of $31,275.00. Following the completion of the transaction, the chief executive officer now owns 5,552,502 shares of the company’s stock, valued at approximately $69,461,800.02. This trade represents a 0.05 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have purchased 10,500 shares of company stock worth $128,459. Corporate insiders own 51.67% of the company’s stock.

Hedge Funds Weigh In On Greenwich LifeSciences

Several institutional investors and hedge funds have recently bought and sold shares of GLSI. Wells Fargo & Company MN raised its holdings in Greenwich LifeSciences by 54.8% during the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company’s stock valued at $32,000 after acquiring an additional 1,008 shares during the period. Barclays PLC raised its holdings in Greenwich LifeSciences by 12.7% during the fourth quarter. Barclays PLC now owns 9,648 shares of the company’s stock valued at $108,000 after acquiring an additional 1,088 shares during the period. State Street Corp raised its holdings in Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after acquiring an additional 3,005 shares during the period. Brown Brothers Harriman & Co. bought a new stake in Greenwich LifeSciences during the fourth quarter valued at about $45,000. Finally, JPMorgan Chase & Co. raised its holdings in Greenwich LifeSciences by 172.0% during the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock valued at $79,000 after acquiring an additional 4,465 shares during the period. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.